Report ID: SQMIG35H2341
NA
Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Biosimilars Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Biosimilars industry players.
The global biosimilars market has turned out to be a competitive and dynamic market.Major pharmaceutical and biotech firms are investing heavily in biosimilars to capitalize on market opportunities arising from the patent loss of blockbuster biologic medicines. Companies are concentrating on the development of biosimilars against high-revenue biologics, with high concentration on broadening the pipeline of biosimilars into fusion proteins, insulins, and monoclonal antibodies. For example, Sandoz (Novartis), being one of the leaders in the biosimilars market, is now concentrating on oncology and immunology biosimilars, including Zarxio (biosimilar of Neupogen) and Erelzi (biosimilar of Enbrel).
REQUEST FOR SAMPLE
Biosimilars Market size was valued at USD 31.3 Billion in 2024 and is poised to grow from USD 35.71 Billion in 2025 to USD 102.59 Billion by 2033, growing at a CAGR of 14.1% during the forecast period (2026–2033).
Key vendors in the Biosimilars Market include Amgen, Sandoz, Pfizer, Celltrion, Samsung Bioepis, Biocon, Viatris, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories, Roche, Boehringer Ingelheim, and Coherus BioSciences. These companies focus on expanding biosimilar portfolios, improving affordability, and increasing access to biologic treatments globally.
The key driver of the Biosimilars Market is the increasing demand for cost-effective alternatives to expensive biologic drugs. Rising prevalence of chronic diseases, patent expirations of major biologics, growing healthcare expenditure, and supportive regulatory frameworks are further accelerating the adoption and growth of biosimilars globally.
The key market trend in the Biosimilars Market is the increasing adoption of monoclonal antibody biosimilars and expansion of regulatory approvals worldwide. Growing focus on affordable healthcare, strategic collaborations among pharmaceutical companies, and advancements in biologics manufacturing technologies are further supporting the market’s rapid expansion globally.
North America accounted for the largest share in the Biosimilars Market due to increasing adoption of cost-effective biologic alternatives, rising healthcare expenditure, and favorable regulatory support. The presence of major pharmaceutical companies, growing prevalence of chronic diseases, and expanding biosimilar approvals are further driving regional market growth.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2341
sales@skyquestt.com
USA +1 351-333-4748